Trial Profile
Randomized clinical trial to assess the impact of treatment with empagliflozine on systemic inflammatory and renal parameters in patients with Diabetes Mellitus type 2 and ischemic heart disease.
Status:
Recruiting
Phase of Trial:
Phase IV
Latest Information Update: 13 Jun 2018
Price :
$35
*
At a glance
- Drugs Empagliflozin (Primary)
- Indications Myocardial infarction; Type 2 diabetes mellitus
- Focus Biomarker; Pharmacodynamics
- Acronyms ENDURANCE
- 13 Jun 2018 New trial record